Biogen Inc. (BIIB)
After hours:
| Previous Close | 193.18 |
| Open | 198.97 |
| Bid | 201.78 x 100 |
| Ask | 202.03 x 100 |
| Day's Range | 198.97 - 205.75 |
| 52 Week Range | 189.44 - 319.76 |
| Volume | |
| Avg. Volume | 1,201,566 |
| Market Cap | 29.361B |
| Beta (5Y Monthly) | -0.01 |
| PE Ratio (TTM) | 25.31 |
| EPS (TTM) | 7.98 |
| Earnings Date | Apr 24, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 297.80 |
- Yahoo Finance Video
Biogen stock rises on Q1 results, Alzheimer's drug sales
Shares of the biopharmaceutical company Biogen (BIIB) are on the rise Wednesday, buoyed by the company's first quarter results. The company beat profit expectations, driven by Biogen's cost-cutting initiatives and the boost in sales for its Alzheimer's drug, Leqembi. Yahoo Finance's Anjalee Khemlani breaks down the details of the report. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Angel Smith
Investor's Business DailyBiogen Stock Surges After Two Notable Products Walloped Sales Expectations
Two of Biogen's newest drugs walloped first-quarter sales expectations on Wednesday, and helped Biogen stock jump.
ZacksBiogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.
